Dr. Colburn Curriculum Vitae 2012 - Center for Cancer Research ...

Name: Nancy Hall Colburn, Ph.D. 

Citizenship: United States 

Education: 

CURRICULUM VITAE 

May, 2012 

1963 B.A., Chemistry, Swarthmore College, Swarthmore, PA 

1967 Ph.D., Biochemistry, McArdle Laboratory for Cancer Research, University of 

Wisconsin, Madison, WI 

Brief Chronology of Employment: 

1968-1972 Assistant Professor, Department of Biological Sciences, University of Delaware 

(Two-thirds time), Newark, DE 

1972-1974 NIH Special Research Fellow, Department of Dermatology, University of Michigan, 

Ann Arbor, MI 

1974-1975 Assistant Professor, Departments of Dermatology & Biological Chemistry, 

University of Michigan, Ann Arbor, MI 

1975-1976 Visiting Scientist and Consultant, Department of Environmental and Industrial 

Health, University of Michigan, Ann Arbor, MI 

1976-1979 Expert, Laboratory of Experimental Pathology, DCCP, NCI, Bethesda, MD 

1979-1984 Expert and Acting Chief, Cell Biology Section, Laboratory of Viral Carcinogenesis, 

BCP, DCE, NCI, NIH, Frederick, MD 

1984-6/96 Chief, Cell Biology Section, Laboratory of Viral Carcinogenesis, DBS, NCI, NIH, 

Frederick, MD 

7/96-2/99 Chief, Gene Regulation Section, Laboratory of Biochemical Physiology, DBS, NCI, 

NIH, Frederick, MD 

3/99-10/03 Chief, Gene Regulation Section, Basic Research Laboratory, DBS, NCI, NIH, 

Frederick, MD 

11/03 - Date Chief, Laboratory of Cancer Prevention, CCR, NCI and Chief, Gene Regulation 

Section 

Societies: 

American Society for Biological Chemistry and Molecular Biology 

American Association for Cancer Research 

New York Academy of Sciences 

American Association for the Advancement of Science 

Sigma XI

Honors and Other Special Scientific Recognition 

Editorial Board Memberships: 

Molecular Carcinogenesis, 1986-Date 

Biochemica et Biophysica Acta, 1997-2005 

Cancer Research, 1989-1990 

International Journal of Cancer, 1984-2003 

Journal of Cancer Research and Clinical Oncology, 1990-Date 

Oncology Research, 1988-1997 

Teratogenesis, Carcinogenesis, and Mutagenesis, 1980-1989 

Cancer Prevention Research, 2008-Date 

Scientific Advisory Board Memberships: 

Chemical Industries Institute of Technology, 1990-1998 

University of Nebraska Cancer Center, 1991-1999 

Michigan State University Cancer Center, 1991-1999 

Yonsei University Medical School Genetics Institute, 1992-Date 

American Cancer Society, Inc., Council for Extramural Grants, 1996-2000 

Sealy Fund for Biomedical Research, University of Texas, Galveston, 1992-2002 

Mouse Models of Human Cancer Leadership Team on Prevention, 2010-date 

2 

Nancy H. Colburn, Ph.D. 

Study Section and Site Visit Team Memberships: 

Member, NIH Chemical Pathology Grant Study Section, 1979-1983 

Member, Site Visit Teams for NIH Grants Program, 1981-Date 

Member, Advisory Groups to Environmental Protection Agency, Center for Disease Control and 

Veterans Administration Innovative Carcinogenesis Program, 1982, 1983 

Member, Basic Science Program Project (CAK) NCI Grant Study Section, 1985-1988 

Member, Site Visit Teams for the German Cancer Research Center, Heidelberg, 1985, 2005, 2010 

Chair or Member, 35 NIH PO-1 Site Visits, 1986-Date 

Member, American Cancer Society Carcinogenesis and Nutrition Grants Study Section, 1990- 

1993, and Chair 1992-1993 

Chair, 1994-2000, International Union against Cancer (UICC) Fellowships Committees, Member, 

1991-2000 

Member, Site Visit Teams for DOE Pacific Northwest National Laboratory, 1999-2000 

Member, Cell Development and Function (CDF), NIH, Study Section, 2000 

Organizing Committees for National and International Symposia: 

Member, Program Committee, American Association for Cancer Research, 1980, 1985 

Organizer, Symposium on Oncogenes at AACR Annual Meeting, 1980 

Member of Organizing Committee, Chemical Pathology Study Section Workshop on the Role of

3 


Free Radicals in Tumor Promotion, 1982 

Organizer, Keystone Symposium on Growth Factors, Tumor Promoters and Cancer Genes, 1986 

Organizer, 1987 FASEB Summer Conference on Mechanisms of Carcinogenesis 

Chair, American Cancer Society Workshop on Tumor Promotion, 1987 

Organizer, Symposium on Signal Transduction at FASEB Annual Meeting, 1988 

Organizer, ACS Schilling Conference on Molecular Targets for Cancer Prevention, 2000 

Presenter and Chair, ACS Science Writers Symposium, 2001 

Organizer, Iowa State University Conference on Molecular Targets for Nutritional 

Intervention, 2002 

Chair, Symposium on Molecular Targets for Prevention, AACR Annual Meeting, 2003 

Chair, Symposium on Transcription Factors as Chemopreventive Targets, AACR Annual 

Meeting, 2005 

Co-Chair, Keystone Symposium, Molecular Targets for Cancer Prevention, 2006 

Chair, AACR Frontiers in Cancer Prevention, Educational Session on Targeting Translation 

for Cancer Prevention, 2007 

Scientific Society Committees and Boards: 

Chair, Rhoads Award Committee AACR, and Member, Advisory Board Nominating 

Committee and Clowes Award Committee, AACR, 1985-87, Exhibits Committee 1990-1991 

Member, Board of Directors, AACR, 1990-1993 

President, AACR Women in Cancer Research, 1994-1995 

Postdoctoral and Sabbatical Fellows Mentored 1980-Date: 55 

AACR Cancer Prevention Awards Committee 2008-2010 

Ph.D. Committees and University Affiliations: 

Alan Lau, University of Michigan, 1975 

Don Miller, Oak Ridge National Labs, 1979 

Sylvie Poirier, INSERM, Lyon, France, 1988-1990 

Lenora Garrett, University of Mississippi, 1988-1989 

PhD Mentor of 

Lori Bernstein, Johns Hopkins University, 1987-1989 

Hyung-tae Kim, George Washington University, 1992-1997 

Halina Zakowicz, George Washington University, 2001-2004 

Adjunct Professor, Ph.D. program in Genetics, George Washington University, 1990-Present 

Adjunct Professor, University of Maryland, Department of Pathology 

Ph.D. Committees at George Washington (Genetics Program): C. Granville, E. Flynn, M. 

Ortiz, H. Lu, E. Krasnikas, A. Howard, M. Ring, C. McCauslin, F. Forozan, N. Malik, C. 

Cultraro, S. Soyal, L. daSilva, J. Smith, C. Hollander, K. Muszynski, S. Storm 

Preceptorships: 

Advisor for more than 90 undergraduate or high school research students, 1968-Date 

Advisor to 8 Dermatology residents doing research rotations, 1972-1976

4 


Advisor to 40 medical students, postbaccalaureate fellows, and MS students, 1975-date 

Distinguished Lecturer/ Endowed Lectureships: 

"New Directions in Cancer Research" at University of Texas Medical Center, Galveston, 1984 

"Frontiers in Biological Sciences" at Case Western Reserve University, 1990 

"Transcription Factors as Effectors of Signal Transduction" as Eppley Visiting Professor of 

Oncology, Eppley Institute, University of Nebraska, 1994 

“Promising Molecular Targets for Cancer Prevention” at Science Park Research Division, 

M.D. Anderson Cancer Center, 2004 

“New Molecular Targets for Cancer Prevention”, Grand Rounds at M.D. Anderson Cancer 

Center, Houston, 2004 

“Novel tumor suppressor Pdcd4 inhibits translation selectively to inhibit AP-1 and 

tumorigenesis”, Distinguished Scientist Series, Wake Forest Medical School, 2007 

“Pdcd4 targets translation to block tumorigenesis and tumor progression”, Bloch Lecture, U of 

Louisville, 2008 

Keynote: Okayama University Symposium for Future Technology, Okayama, Japan, 2012 

Competitive Awards for Research Support: 

University of Delaware Research Foundation Grants, 1969-1971 

NIH RO-1 Grant entitled: "Methylation of Skin Tumor Ribosomal RNA," awarded 1972 

NIH Special Research Fellowship, University of Michigan, 1972-74 

American Cancer Society/University of Michigan Institutional Research Grant entitled, 

"Oncogenic Transformation in Cell Culture", 1974-75 

NIH CREG grant on in vitro Carcinogenesis, awarded 1976 

NIH RO-1 Grant on Molecular Mechanisms of Preneoplastic Progression, awarded 1979 

DOE OBER Low Dose Radiation Grant, as co-PI, 2000-2003 

NIH Office of Complementary and Alternative Medicine on Identification of Response 

Indicators to Dietary Intervention to Prevent Colon Cancer, as Co-PI, 2008-2009 

NCI Office of Complementary and Alternative Medicine on Use of Traditional Chinese 

Medicine to Prevent Colon Cancer, as Co-PI, 2012-2013 

NIH Office of Dietary Supplements on Dietary interventions to Prevent Colon Cancer and 

Discover Predictive Biomarkers, as Co-PI 2011-2012 

Postdoctoral Fellows and Professors on Sabbatical have joined our laboratory on Fellowship 

awards (1983-date) from the following sources: 

NIH (NRSA) 

WHO 

UICC 

Sankyo, Ltd, Japan

5 


Ministry of Education, Science, and Culture of Japan, Shizuoka University, Japan 

INSERM - NCI Bilateral Agreement 

FUSO Pharmaceutical, Japan 

American Health Foundation 

Georgetown University School of Medicine 

Rockefeller Foundation 

Triton Biosciences, Oakland, CA 

Indo-US (CFTRI-NIH) Award 

Japan Society for the Promotion of Science 

Nanjing Medical University, Guangzhou 

NCI Office of Dietary Supplements 

NIH Office of Complementary and Alternative Medicine 

Patent Awarded: "Dominant Negative Deletion Mutants of c-Jun and Their Use in the 

Prevention and Treatment of Cancer", U.S. Patent Number 6,699,842 

Other Awards and Honors: 

PMRS Performance Award, 1986-1990 

Elected a Fellow of the Conte Environmental Health Institute, Berkshire Health Systems, 

Pittsfield, Massachusetts, 1989 

National Cancer Institute Technology Transfer Award, 2000, 2009 

NIH Merit Award, 2002 

NCI Outstanding Mentor Award, 2002 

NCI Mentor of Merit Award, 2008 

“Carcinogenesis to Chemoprevention”, a Conference in my honor, NCI Frederick, 2010 

NCI Women Scientists Advisors Award, Outstanding Mentor of Women Scientists, 2011 

NCI Committees: 

Chair, NCI Cancer Prevention Faculty, 2001-2005 

Member, NCI Animal Models Initiative, 2002-2005 

Chair, Distinguished Scientist Seminar Series, NCI, Frederick, 2002-2007 

Member, NCI Preclinical Models Strategy Team, 2002-2005 

Member, Epidemiology and Carcinogenesis Faculty Steering Committee, 2001-2003 

Chair, NIH Interest Group Conference on Transcription Factors, 1999 

Chair, Search Committee for Head, Molecular Technology Laboratory, NCI, Frederick, 1999 

Program Chair, NCI-USAMRIID Frederick Spring Research Festival, 1998 

Member, Search Committee for Head, NIAID Transgenic Mouse Facility, 1998 

Member, Oversight Committee, NCI/DCE Contracts, 1986-90 

Member, Search Committee for Director, CCR Cancer and Inflammation Program, 2005 

Chair, Cancer Prevention Think Tank, 2006 

Member, CCR Tenure Track Search Committees, Laboratory of Cancer Biology and Genetics, 

2007, Cancer and Inflammation Program, 2007, Laboratory of Human Carcinogenesis, 2007,

6 


Laboratory of Cell and Developmental Genetics 2010 (Chair), Chemical Biology Laboratory 

2010, 2011, 2012 

Member, Cancer Prevention Fellowship Program Science Education Committee, 2008, 2010 

Chair, Molecular Targets for Cancer Prevention Conference, Bethesda, 2009 

Invited to speak at the following Symposia, Universities or Research Institutes (Partial List) 

1980-89 

Keystone Conference on Genes and Cancer 

Keystone Conference on Growth Factors, Tumor Promoters and Cancer Genes 

FASEB Conferences on Carcinogenesis 

University of North Carolina 

German Cancer Research Center 

Princess Takamatsu Symposium on Carcinogenesis 

Cold Spring Harbor Meeting on Molecular Carcinogenesis 

Gordon Conference on Cancer 

Salk Institute 

1990-99 

Cleveland Clinic 

University of Toronto 

Swiss Institute for Experimental Cancer Research 

Aspen Cancer Conference 

University of Nebraska 

University of Wisconsin 

Washington State University 

Korean Biochemistry Society 

Charles Heidelberger Symposium 

Institute of Molecular Pathology, Vienna 

P53 in Neoplasia Conference, Zurich 

Fred Hutchinson Cancer Research Center 

M.D. Anderson Cancer Center 

Roswell Park Cancer Institute 

Danish Cancer Society 

The Oxygen Society 

Food Factors & Cancer Symposium, Hamamatsu, Japan 

University of Texas, Galveston 

Johns Hopkins Oncology Center 

2000-Date 

Bar-Ilan University, Tel-Aviv, Israel

7 


Weizmann Institute, Rehovot, Israel 

City of Hope Medical Center, California 

International Conference on Oxygen and Nitrogen Radicals 

Charles Heidelberger Memorial Symposium 

University of Vermont 

George Washington University 

Georgetown University 

Pacific Northwest National Laboratory 

Meharry Medical College 

University of Pennsylvania 

ACS Schilling Conference: Molecular Targets for Cancer Prevention 

International Skin Carcinogenesis Conferences, Tucson, Gifu, State College 

Toxicology Society of Korea 

ACS Science Writers Conference 

German Cancer Research Center, Heidelberg 

Molecular Staging of Cancer Conference, Munich 

Gordon Conference on Toxicology 

AACR Annual Meetings: Mouse Models for Cancer Prevention, Molecular Targets for Cancer 

Prevention 

AACR Frontiers in Cancer Prevention Conferences 

International Workshop on AP-1 Transcription Factors, Capri, Italy 

Keystone Conference on Molecular Targets for Cancer Prevention 

M.D. Anderson Cancer Center, Houston and Science Park, Texas 

University of Alabama 

University of Texas, San Antonio 

Biochemistry and Molecular Biology Association, Yokohama, Japan 

Saga University Medical School, Japan 

University of Louisville (KY) Bloch Lecture 

Hormel Institute Frontiers in Cancer Research 

China-Us Forum on Frontiers of Cancer Research, Changsha 

2010-date 

Case-Western University, Cleveland 

NCI Translates, Washington DC 

AACR Conference on Translational Regulation in Cancer, San Diego 

Goethe University- Frankfurt 

Phytochemical Society of North America-Kona, Hawaii 

Fifth International Symposium for Future Technology, Okayama University, Japan 

International Cancer Symposium on Innovative Approaches to Explore Novel Druggable 

Targets, Seoul National University, South Korea

Publications: 

8 


1. Haight GP, Richardson DC, and Colburn NH: A spectrophotometric study of equilibria 

involving mononuclear chromium (IV) species in solutions of various acids. Inorgan. Chem. 

3: 1777-1780, 1964. 

2. Colburn NH, Richardson RF, and Boutwell RK: Studies of the reaction of �-propiolactone 

with deoxyguanosine and related compounds. Biochem. Pharmacol. 14: 1113-1118, 1965. 

3. Colburn NH and Boutwell RK: The binding of �-propiolactone to mouse skin DNA in vivo: 

its correlation with tumor-initiation activity. Cancer Res. 26: 1701-1706, 1966. 

4. Hennings H, Smith HC, Colburn NH, and Boutwell RK: Inhibition by actinomycin D of 

DNA and RNA synthesis and of skin carcinogenesis initiated by 7, 12dimethylbenz[a]anthracene 

of �-propiolactone. Cancer Res. 28: 653-660, 1968. 

5. Colburn NH and Boutwell RK: The binding of �-propiolactone and some related alkylating 

agents to DNA, RNA and protein of mouse skin; relation between tumor-initiating power of 

alkylating agents and their binding to DNA. Cancer Res. 28: 653-660, 1968. 

6. Colburn NH and Boutwell RK: The in vivo binding of �-propiolactone to mouse skin DNA, 

RNA, and protein. Cancer Res. 28: 642-652, 1968. 

7. Colburn NH: Studies on the molecular mechanism of carcinogenesis by �-propiolactone. 

Vox Sanguinis 17: 64, 1969. 

8. Boutwell RK, Colburn NH and Muckerman CC: In vivo reactions of �-propiolactone. Ann. 

NY Acad. Sci. 163: 751-764, 1969. 

9. Voorhees JJ, Colburn NH, Stawiski M, Duell E, Haddox M, and Goldberg, N.: Imbalanced 

cyclic AMP and cyclic GMP levels in the rapidly dividing, incompletely differentiated 

epidermis of psoriasis. In Baserga, R, and Clarkson, B. (Eds.): Control of Proliferation in 

Animal Cells. New York, Cold Spring Harbor Laboratory Press, pp. 635-638, 1974. 

10. Delescluse C, Colburn NH, Duell EA, and Voorhees JJ: Cyclic AMP elevating agents 

inhibit proliferation of keratinizing guinea pig epidermal cells. Differentiation 2: 343-350, 

1974. 

11. Colburn NH, Lau S, and Head RA: Decrease of epidermal histidase activity by tumor 

promoting phorbol esters. Cancer Res. 35: 3154-3159, 1975.

9 


12. Yuspa SH, Lichti U, Ben T, Patterson E, Hennings H, Slaga TJ, Colburn NH, and Kelsey W: 

Phorbol-ester tumor promoters stimulate DNA synthesis and ornithine decarboxylase 

activity in mouse epidermal cell cultures. Nature 262: 402-404, 1976. 

13. Colburn NH, Vorder Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, and Shimada 

T: Correlation of anchorage independent growth with tumorigenicity of chemically 

transformed mouse epidermal cells. Cancer Res. 38: 624-634, 1978. 

14. Colburn NH: Chemical transformation of epidermal cell cultures. In Saffiotti U, and Autrup 

H (Eds.): In Vitro Carcinogenesis. National Cancer Institute. Technical Report Series 44, 

pp. 69-94, 1978. 

15. Colburn NH, Vorder Bruegge WF, Bates J, and Yuspa SH: Epidermal cell transformation in 

vitro. In Slaga TJ, Sivak A, and Boutwell RK (Eds.): Mechanisms of Tumor Promotion and 

Carcinogenesis. New York, Raven Press, pp. 257-271, 1978. 

16. Colburn NH, Former BF, Nelson KA, and Yuspa SH: Tumor promoter induces anchorage 

independence irreversibly. Nature 281: 589-591, 1979. 

17. Colburn NH: The use of tumor promoter responsive epidermal cell lines to study 

preneoplastic progression. In Franks LM, and Wigley CB (Eds.): Neoplastic 

Transformation in Differentiated Epithelial Cell Systems in vitro. New York, Academic 

Press, pp. 113-134, 1979. 

18. Colburn NH: Tumor promotion and preneoplastic progression. In Slaga, T.J. (Ed.): 

Carcinogenesis; Modifiers of Carcinogenesis, Vol. 5. New York, Raven Press, pp. 33-56, 

1980. 

19. Colburn NH, Koehler B, and Nelson KA: A cell culture assay for tumor promoter dependent 

progression toward neoplastic phenotype: detection of tumor promoters and promotion 

inhibitors. Teratogenesis, Carcinog. Mutagen. 1: 87-96, 1980. 

20. Colburn NH: Tumor promoter produces anchorage independence in mouse epidermal cells 

by an induction mechanism. Carcinogenesis 1: 951-954, 1980. 

21. Colburn NH, Ozanne S, Lichti U, Ben T, Yuspa S, Wendel E, Jardini E, and Abruzzo G: 

Retinoids inhibit promoter-dependent preneoplastic progression in mouse epidermal cell 

lines. Ann. NY Acad. Sci. 359: 251-259, 1981. 

22. Hennings H, Devor D, Wenk ML, Slaga TJ, Former B, Colburn NH, Bowden GT, Elgjo K, 

and Yuspa SH: Comparison of two-stage epidermal carcinogenesis initiated by 7,12dimethylbenz(a)anthracene 

or N-methyl-N'-nitro-N-Nitrosoguanidine in newborn and adult

SENCAR and BALB/c mice. Cancer Res. 41: 773-779, 1981. 

10 


23. Colburn NH and Gindhart T: Specific binding of transforming growth factor correlates with 

promotion of anchorage independence in EGF receptorless JB6 cells. Biochem. Biophys. 

Res. Commun. 102: 799-807, 1981. 

24. Colburn NH, Wendel E, and Abruzzo G: Dissociation of mitogenesis and late-stage 

promotion of tumor cell phenotype by phorbol esters: mitogen resistant variants are sensitive 

to promotion. Proc. Natl. Acad. Sci. USA 78: 6912-6916, 1981. 

25. Dion LD, DeLuca L, and Colburn NH: Phorbol ester-induced anchorage independence and 

its antagonism by retinoic acid correlates with altered expression of specific glycoproteins. 

Carcinogenesis 2: 951-958, 1981. 

26. Colburn NH, Dion LD, and Wendel EJ: The role of mitogenic stimulation and specific 

glycoprotein changes in the mechanism of late-stage promotion in JB-6 epidermal cell lines. 

In Hecker E, Fusening NE, Kunz W, Marks F, and Thielmann HW (Eds.): Carcinogenesis: 

A Comprehensive Survey. New York, Raven Press, pp. 231-235, 1982. 

27. Colburn N and Huberman E: Tumor promotion: workshop report. In Harris CC, and Cerutti 

PA (Eds.): Mechanisms of Chemical Carcinogenesis. New York, Alan R. Liss, pp. 499-501, 

1982. 

28. Colburn NH, Wendel E, and Srinivas L: Responses of preneoplastic epidermal cells to tumor 

promoters and growth factors: use of promoter resistant variants for mechanism studies. J. 

Cell. Biochem. 18: 261-270, 1982. 

29. Srinivas L and Colburn NH: Ganglioside changes induced by tumor promoters in 

promotable JB6 mouse epidermal cells: antagonism by an antipromoter. J. Natl. Cancer 

Inst. 68: 469-473, 1982. 

30. Colburn NH, Gindhart T, Hegamyer GA, Blumberg PM, Delclos KB, Magun BE, and 

Lockyer L: Phorbol diester and EGF receptors in TPA-resistant and TPA-sensitive mouse 

epidermal cells. Cancer Res. 42: 3093-3097, 1982. 

31. Srinivas L, Gindhart TD, and Colburn NH: Tumor-promoter-resistant cells lack 

trisialoganglioside response. Proc. Natl. Acad. Sci. USA 79: 4988-4991, 1982. 

32. Dion LD, Bear J, Bateman J, Deluca LM, and Colburn NH: Inhibition by tumor-promoting 

phorbol ester of procollagen synthesis in promotable JB6 mouse epidermal cells. J. Natl. 

Cancer Inst. 69: 1147-1154, 1982.

11 


33. Colburn NH, Talmadge CB, and Gindhart TD: Transfer of sensitivity to tumor promoters by 

transfection of DNA from sensitive into insensitive mouse JB6 epidermal cells. Mol. Cell. 

Biol. 3: 1182-1186, 1983. 

34. Colburn NH, Gindhart TD, Dalal B, and Hegamyer GA: The role of phorbol ester receptor 

binding in responses to promoters by mouse and human cells. In Langenbach, R., Nesnow, 

S., and Rice, J. (Eds.): Organ and Species Specificity in Chemical Carcinogenesis. New 

York, Plenum Publishing Corp., pp. 189-200, 1983. 

35. Colburn NH, Talmadge CB, and Gindhart TD: Transfer of phorbol ester promotability by 

transfection of DNA from promotable into nonpromotable cells. In Cohn WE (Ed.): 

Progress in Nucleic Acid Research and Molecular Biology. New York, Academic Press, pp. 

107-110, 1983. 

36. Copley M, Gindhart T, and Colburn N: Hexose uptake as an indicator of JB6 mouse 

epidermal cell resistance to the mitogenic activity of TPA. J. Cell. Physiol. 114: 173-178, 

1983. 

37. Sobel ME, Dion LD, Vuust Jens, and Colburn NH: Tumor promoting phorbol esters inhibit 

procollagen synthesis at a pretranslational level in JB6 mouse epidermal cells. Mol. Cell. 

Biol. 3: 1527-1532, 1983. 

38. Srinivas L, and Colburn NH: Reduced trisialoganglioside synthesis in chemically but not 

mos-transformed mouse epidermal cells. Cancer Res. 44: 1510-1514, 1984. 

39. Fleischmann WR Jr, Newton RC, Fleischmann CM, Colburn NH, and Brysk MM: 

Discrimination between nonmalignant and malignant cells by combinations of IFN-γ plus 

IFN-α/β. J. Bio. Response Mod. 3: 397-405, 1984. 

40. Srinivas L and Colburn NH: Preferential oxidation of cell surface sialic acid by periodate 

leads to promotion of transformation in JB6 cells. Carcinogenesis 5: 515-519, 1984. 

41. Colburn NH, Lerman MI, Srinivas L, Nakamura Y, Hegamyer GA, and Gindhart TD: 

Membrane and genetic events in tumor promotion: studies with promoter resistant variants 

of JB6 cells. Princess Takamatsu Symposium. In Fujiki, H. (Ed.): Cellular Interactions by 

Environmental Tumor Promoters. Tokyo, Japan Sci. Soc. Press, pp. 155-166, 1984. 

42. Colburn NH, Lerman MI, Srinivas L, Nakamura Y, Hegamyer GA, and Gindhart TD: 

Genetic determinants of tumor promotion: studies with promoter resistant variants of JB6 

cells. In Bishop M, Graves M, and Rowley T (Eds.): Genes and Cancer, Vol. 17. New 

York, Alan R. Liss, pp. 137-155, 1984.

12 


43. Colburn NH, Srinivas L, Hegamyer GA, Dion LD, and Wendel EJ: Role of specific 

membrane and genetic changes in the mechanism of tumor promotion. Studies with 

promoter-resistant variants. In Borsonyi, M. (Ed.): The Role of CoCarcinogens and 

Promoters in Human and Experimental Carcinogenesis. Lyon, France, IARC Publication, 

pp. 205-215, 1984. 

44. Colburn NH, Lerman MI, Hegamyer GA, and Gindhart TD: A transforming activity not 

detected by DNA transfection to NIH 3T3 cells is detected by JB6 mouse epidermal cells. 

Mol. Cell. Biol. 5: 890-893, 1985. 

45. Gindhart TD, Srinivas L, and Colburn NH: Benzoyl peroxide promotion of transformation 

of JB6 mouse epidermal cells: inhibition by ganglioside GT but not retinoic acid. 


46. Nakamura Y, Colburn NH, and Gindhart TD: Role of reactive oxygen in tumor promotion: 

implication of superoxide anion in promotion of neoplastic transformation in JB-6 cells by 

TPA. Carcinogenesis 6: 229-235, 1985. 

47. Gindhart TD, Nakamura Y, Stevens LA, Hegamyer GA, West MW, Smith BM, and Colburn 

NH: Genes and signal transduction in tumor promotion: conclusion from studies with 

promoter resistant variants of JB6 mouse epidermal cells. In Mass, M. (Ed.): 

Carcinogenesis: A Comprehensive Survey. Tumor Promotion and Enhancement in the 

Etiology of Human and Experimental Respiratory Tract Carcinogenesis. New York, Raven 

Press, Vol. 8, pp. 341-367, 1985. 

48. Colburn NH: Genes and membrane signals involved in neoplastic transformation. In 

Huberman E and Barr SH (Eds.): Carcinogenesis: A Comprehensive Survey. The Role of 

Chemicals and Radiation in the Etiology of Cancer. New York, Raven Press, Vol. 10, pp. 

235-248, 1985. 

49. Diwan BA, Ward JM, Rice JM, Colburn NH, and Spangler EF: Tumor-promoting effects of 

di(2-ethylhexyl)phthalate in JB6 mouse epidermal cells and mouse skin. Carcinogenesis 6: 

343-347, 1985. 

50. Lerman MI, Hegamyer GA, and Colburn NH: Cloning and characterization of putative genes 

that specify sensitivity to induction of neoplastic transformation by tumor promoters. Int. J. 

Cancer 37: 293-302, 1986. 

51. Smith BM, Gindhart TD, and Colburn NH: Extracellular calcium requirement for 

promotion of transformation in JB6 cells. Cancer Res. 46: 701-706, 1986. 

52. Hosoi J, Abe E, Suda T, Colburn NH, and Kuroki T: Induction of anchorage-independent

13 


growth of JB6 mouse epidermal cells by 1,α25-Dihydroxy vitamin D3 1 . Cancer Res. 46: 

5582-5586, 1986. 

53. Takahashi K, Heine UI, Junker JL, Colburn NH, and Rice JM: Role of cytoskeleton changes 

and expression of the H-ras oncogene during promotion of neoplastic transformation in 

mouse epidermal JB6 cells. Cancer Res. 46: 5923-5932, 1986. 

54. Smith BM, Gindhart TD, and Colburn NH: Possible involvement of a lanthanide sensitive 

protein kinase C substrate in lanthanide promotion of neoplastic transformation. 


55. Lerman MI, Sakai A, Yao K-T, and Colburn NH: DNA sequences in human nasopharyngeal 

carcinoma cells that specify susceptibility to tumor promoter-induced neoplastic 

transformation. Carcinogenesis 8: 121-127, 1987. 

56. Shimada T, Gindhart TD, Lerman M, and Colburn NH: Lifespan extension of basal cell 

nevus syndrome fibroblasts by transfection with mouse pro or v-myc genes. Int. J. Cancer 

39: 649-655, 1987. 

57. Colburn NH and Smith BM: Genes that cooperate with tumor promoters in transformation. 

J. Cell. Biochem. 34: 129-142, 1987. 

58. Colburn NH, Moses HL, and Stanbridge EJ (Eds.): Growth Factors, Tumor Promoters, and 

Cancer Genes, Vol. 58. New York, AR Liss, pp. 410, 1987. 

59. Colburn NH: The genetics of tumor promotion. In Barrett JC (Ed.): Mechanisms of 

Environmental Carcinogenesis, Vol. 1. Boca Raton, CRC Press, Inc., 1987, pp. 81-95. 

60. Seed JL, Nakamura Y, and Colburn NH: Implication of superoxide radical anion in 

promotion of neoplastic transformation in mouse JB6 cells by TPA. In Cerutti PA, Nygaard 

OF, and Simic MG (Eds.): Anticarcinogenesis and Radiation Protection. New York, 

Plenum Press, pp. 175-181, 1987. 

61. Colburn NH, Farber E, Weinstein IB, Diamond L, and Slaga TJ: Meeting Report: American 

Cancer Society workshop conference on tumor promotion and antipromotion. Cancer Res. 

47: 5509-5513, 1987. 

62. Lerman MI and Colburn, NH: Pro genes, a novel class of genes that specify sensitivity to 

induction of neoplastic transformation by tumor promoters. In Langenbach R, Barrett JC, 

and Elmore E (Eds.): Tumor Promoters: Biological Approaches for Mechanistic Studies 

and Assay Systems. New York, Raven Press, pp. 357-385, 1988.

14 


63. Smith BM and Colburn NH: Protein kinase C and its substrates in tumor promoter-sensitive 

and -resistant cells. J. Biol. Chem. 263: 6424-6431, 1988. 

64. Colburn NH, Smith BM, Wendel EJ, Dowjat WK, and Shimada T: Transfer by pro gene 

transfection of tumor promoter-sensitive phenotype to promotion-insensitive JB6 cells. 

Cancer Res. 48: 1195-1200, 1988. 

65. Nakamura T, Gindhart TD, Winterstein D, Tomita I, Seed JL, and Colburn NH: Early 

superoxide dismutase-sensitive event promotes neoplastic transformation in mouse 

epidermal JB6 cells. Carcinogenesis 9: 203-207, 1988. 

66. Dowjat KW, Cao Y, Nagashima K, Sakai A, and Colburn NH: Comparison of P + active and 

inactive pro-1 homologs from human nasopharyngeal carcinoma cells. Mol. Carcinog. 1: 

33-40, 1988. 

67. Garrity RR, Seed JL, Young HA, Winterstein D, and Colburn NH: Evidence that mouse 

promotion-sensitivity gene pro-1 is transcribed by RNA polymerase III. Gene 68: 63-72, 

1988. 

68. Colburn NH, Smith BM, Wendel EJ, Nakamura Y, and Winterstein D: Comparison of 

mouse pro-1 and pro-2 transfectants for responses to tumor promoters and antipromoters. 


69. Dion LD, Gindhart TD, and Colburn NH: Four-day duration of tumor promoter exposure 

required to transform JB6 P+ cells to anchorage independence. Cancer Res. 49: 7126-7131, 

1988. 

70. Colburn NH (Ed.): Genes and Signal Transduction in Multistage Carcinogenesis. New 

York, Marcel Dekker, 461 pages, 1989. 

71. Garrity RR, Smith BM, and Colburn NH: Genes and signals involved in tumor promoter 

induced transformation. In Colburn NH (Ed.): Genes and Signal Transduction in Multistage 

Carcinogenesis. New York, Marcel Dekker, pp. 139-166, 1989. 

72. Bernstein LR and Colburn NH: AP-1/jun function is differentially induced in promotion 

sensitive and resistant JB6 cells. Science 244: 566-569, 1989. 

73. Simek SL, Kligman D, Patel J, and Colburn NH: Differential expression of an 80-kDa PKC 

substrate in preneoplastic and neoplastic mouse JB6 cells. Proc. Natl. Acad. Sci. USA 86: 

7410-7414, 1989. 

74. Colburn NH, Raab-Traub N, Becker Y, Cao Y, and Winterstein D: Transforming activity of

15 


nasopharyngeal carcinoma DNA detectable in mouse JB6 cells. Int. J. Cancer 44: 1012- 

1016, 1989. 

75. Garrity RR, Hegamyer GA, Seed JL, and Colburn NH: Deletion mapping of tumor 

promotion susceptibility gene pro-1 implicates an RNA polymerase III transcription unit. 

Mol. Carcinog. 3: 243-250. 1990. 

76. DeBenedetti F, Colburn NH, Oppenheim JJ, Faltynek CR: Tumor necrosis factor induces 

anchorage independent growth of two murine non-transformed cell lines. In Oppenheim JJ, 

Powanda M, Kluger M, Dinarello C (Eds.): Molecular and Cellular Biology of Cytokines. 

Wiley-Liss, Inc., pp. 275-280, 1990. 

77. De Benedetti F, Falk L, Ruscetti FW, Colburn NH, Faltynek CR, and Oppenheim JJ: 

Synergistic inhibition of phorbol ester induced transformation of JB 6 cells by transforming 

growth factor-β and retinoic acid. Cancer Res. 51: 1158-1164, 1991. 

78. Bernstein L, Ben-Ari E, Simek S, and Colburn NH: Gene regulation and genetic 

susceptibility to neoplastic transformation: AP-1 and p80 expression in JB6 cells. Environ. 

Health Perspect. 93: 111-119, 1991. 

79. Cao Y, Sun Y, Poirier S, Winterstein D, Hegamyer GA, Seed J, Malin S, and Colburn NH: 

Isolation and partial characterization of a transformation-associated sequence from human 

nasopharyngeal carcinoma. Mol. Carcinog. 4: 297-307, 1991. 

80. Sun Y, Poirier S, Hegamyer GA, and Colburn NH: Isolation and characterization of a 

transformation associated gene from human nasopharyngeal carcinoma cells. In Rhim JS and 

Dritschilo A (Eds.): Neoplastic Transformation in Human Cell Systems in vitro. Clifton, 

NJ, The Humana Press Inc., pp. 203-212, 1991. 

81. Sun Y, Pommier Y, and Colburn NH: Acquisition of a growth inhibitory response to 

phorbol ester involves DNA damage. Cancer Res. 52: 1907-1915, 1992. 

82. Sun Y, Hegamyer GA, and Colburn NH: A simple method using PCR for direct sequencing 

of genomic DNA from frozen tumor tissue embedded in optimal cutting temperature 

compound. Biotechniques 12: 639-640, 1992. 

83. Hirano K, Smith BM, and Colburn NH: Differential induction of 15 and 16 kDa nuclear 

proteins in promotion sensitive and promotion resistant mouse JB6 cells. Oncology Res. 4: 

17-21, 1992. 

84. Ben-Ari ET, Bernstein LR, and Colburn NH: Differential c-jun expression in response to 

tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation. Mol.

Carcinog. 5: 62-74, 1992. 

16 


85. Colburn NH: Gene regulation by active oxygen and other stress inducers: role in tumor 

promotion and progression. In Spatz L, and Bloom A. (Eds.): Biological Consequences of 

Oxidative Stress: Implications for Cardiovascular Disease and Carcinogenesis. Oxford, 

England, Oxford University Press, pp. 121-137, 1992. 

86. Sun Y, Hegamyer GA, Cheng Y-J, Hildesheim A, Chen J-Y, Chen I-H, Cao Y, Yao K-T, and 

Colburn NH: An infrequent point mutation of the p53 gene in human nasopharyngeal 

carcinoma. Proc. Natl. Acad. Sci. USA 89: 6516-6520, 1992. 

87. Simek SL, Fields AP, Colburn NH, Winkler-Pickett R, and Young HA: The presence in a 

mouse T-cell line of a 97 kDa protein kinase C with characteristics similar to known 

members of the novel PKC subgroup and its possible role in lymphocyte gene expression. J. 

Immunol. 149: 3542-3549, 1992. 

88. Bernstein LR, Bravo R, and Colburn NH: 12-0-Tetradecanoylphorbol-13-Acetate-induced 

levels of AP-1 proteins: A 46-kDa protein immunoprecipitated by anti-fra-1 and induced in 

promotion-resistant but not promotion-sensitive JB6 cells. Mol. Carcinog. 6: 221-229, 

1992. 

89. Sun Y, Hegamyer GA, and Colburn NH: Nasopharyngeal carcinoma shows no detectable 

retinoblastoma susceptibility gene alterations. Oncogene 8: 791-795, 1993. 

90. Sun Y, Nakamura K, Wendel E, and Colburn NH: Progression toward tumor cell phenotype 

is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from 

nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. 90: 2827-2831, 1993. 

91. Sun Y, Dong Z, Nakamura K, and Colburn NH: Dosage-dependent dominance over wildtype 

p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J. 7: 944-950, 

1993. 

92. Sun Y, Nakamura K, Hegamyer GA, Dong Z, and Colburn NH: No point mutation of H-ras 

or p53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 

cell variants. Mol. Carcinog. 8: 49-57, 1993. 

93. Sun Y, Hegamyer GA, and Colburn N: PCR-direct sequencing of a GC-rich region by 

inclusion of 10% DMSO: Application to mouse c-jun. BioTechniques 15: 372-374, 1993. 

94. Sun Y, Hegamyer GA, and Colburn NH: Sequence of manganese superoxide dismutaseencoding 

cDNAs from multiple mouse organs. Gene 131: 301-302, 1993.

17 


95. Sun Y, Colburn NH, and Oberley LW: Depression of catalase gene expression after 

immortalization and transformation of mouse liver cells. Carcinogenesis 14: 1505-1510, 

1993. 

96. Sun Y, Colburn NH, and Oberley LW: Decreased expression of manganese superoxide 

dismutase mRNA and protein after immortalization and transformation of mouse liver cells. 

Oncology Res. 5: 127-132, 1993. 

97. Simek SL, Kozak CA, Winterstein D, Hegamyer GA, and Colburn NH: Sequence and 

localization of a novel FK 506 binding protein to mouse chromosome 11. Genomics 18: 

407-409, 1993. 

98. Sun Y, Hegamyer GA, Nakamura K, Kim H-T, Oberley LW, and Colburn NH: Alterations 

of the p53 tumor-suppressor gene in transformed mouse liver cells. Int. J. Cancer. 55: 952- 

956, 1993. 

99. Dong Z, and Colburn NH: AP-1: A molecular target for prevention of carcinogenesis. In 

Srivastava S. (Ed.): Molecular Markers of Early Detection of Cancer. Futura Publishing 

Corp., pp. 123-130, 1994. 

100. Dong Z, Birrer M, Watts R, Matrisian L, and Colburn NH: Blocking of tumor promoterinduced 

AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. 

Natl. Acad. Sci. USA 91: 609-613, 1994. 

101. Sun Y, Hegamyer GA, and Colburn NH: Molecular cloning of five mRNAs differentially 

expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: One is homologous to 

human tissue inhibitor of metalloproteinase-3. Cancer Res. 54: 1139-1144, 1994. 

102. Bernstein LR, Ferris DK, Colburn NH, and Sobel ME: A family of MAP kinase related 

proteins interacts in vivo with the AP-1 transcription factor. J. Biol. Chem. 269: 9401-9404, 

1994. 

103. Dong Z, Cmarik JL, Wendel EJ, and Colburn NH: Differential transformation efficiency but 

not AP-1 induction under anchorage dependent and independent conditions. Carcinogenesis 

15: 1001-1004, 1994. 

104. Cmarik JL, Herschman H, and Colburn NH: Preferential primary response gene expression 

in promotion-resistant vs. promotion-sensitive JB6 cells. Mol. Carcinog. 11: 115-124, 1994. 

105. Claudio PP, Howard CM, Baldi A, De Luca A, Condorelli G, Sun Y, Colburn NH, Calabretta 

B, and Giordano A: p130/pRb2 has similar yet distinctive growth suppressive properties as 

retinoblastoma family members, pRb and p107 1 . Cancer Res. 54: 5556-60, 1994.

18 


106. Watts R, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E, and Colburn, NH: 

c-jun and multistage carcinogenesis: Overexpression of introduced c-jun is associated with 

progression toward a neoplastic endpoint in mouse JB6 cells sensitive but not resistant to 

tumor promoter induced transformation. Mol. Carcinog. 13: 27-36, 1995. 

107. Sun Y, Hildesheim A, Hua L, Yan L, Chen J-Y, Cheng Y-J, Hayes RB, Rothman N, B, W-F, 

Cao Y, Yao K-T, Lanier AP, Hegamyer GA, El-Deiry WS, Xiong Y, and Colburn NH: No 

point mutation but a codon 31 ser->arg polymorphism of the WAF-1/CIP-1/p21 tumor 

suppressor gene in nasopharyngeal carcinoma (NPC): The polymorphism distinguishes 

Caucasians from Chinese. Cancer Epid. Bio. Prev. 4: 261-267, 1995. 

108. Sun Y, Hildesheim A, Lanier AP, Cao Y, Yao K-T, Raab-Traub N, and Yang C-S: No 

point mutation but decreased expression of the /16/MTS1 tumor suppressor gene in 

nasopharyngeal carcinomas. Oncogene 10: 785-788, 1995. 

109. Sun Y, Dong Z, Jackman J, Hegamyer GA, Kim H, Sithanandam K, and Colburn NH: Status 

of the MDM-2 and WAF-1 genes in mouse epidermal JB6 variants harboring wild-type p53: 

A p53-independent induction of WAF-1. Int. J. Oncology 6: 465-471, 1995. 

110. Sun Y, Hildesheim A, Li H, Lanier AP, Cao Y, Yao K-T, Yang C-S, and Colburn NH: The 

von Hippel-Landau disease tumor suppressor gene is not mutated in nasopharyngeal 

carcinomas. Int. J. Cancer 61: 437-438, 1995. 

111. Dong Z, Lavrovsky V, and Colburn N: Transformation reversion induced in JB6 RT101 

cells by AP-1 inhibitors. Carcinogenesis 16: 749-756, 1995. 

112. Dong Z, Watts RG, Sun Y, Zhan S-N, and Colburn NH: Progressive elevation of AP-1 

activity during preneoplastic-to-neoplastic progression as modeled in JB6 cell variants. Int. 

J. Oncol. 7: 359-364, 1995. 

113. Sun Y, Hegamyer GA, Kim H, Sithanandam Li H, Watts R, and Colburn NH: Molecular 

cloning of mouse tissue inhibitor of metalloproteinases-3 (mTIMP-3) and its promoter: 

Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J. 

Biol. Chem. 270: 19312-19319, 1995. 

114. Singh N, Sun Y, Nakamura K, Smith MR, and Colburn NH: c-Jun/AP-1 as possible 

mediators of tumor necrosis factor-α-induced apoptotic response in mouse JB6 tumor cells. 

Oncology Res. 7: 353-362, 1995. 

115. Li J-J, Dong Z, Dawson MI, and Colburn NH: Inhibition of tumor promoter-induced 

transformation by retinoids that transrepress AP-1 without transactivating retinoic acid

esponse element. Cancer Res. 56: 483-489, 1996. 

19 


116. Xu R-H, Dong Z, Maeno M, Kim J, Ueno N, Sredni D, Colburn NH, and Kung H-F: 

Involvement of ras/raf-AP-1 in BMP-4 signaling during early Xenopus development. Proc. 

Natl. Acad. Sci. 93: 834-838, 1996. 

117. Lavrovsky V, Dong Z, Ma WY, and Colburn N: Drug induced reversion of progression 

phenotype is accompanied by reversion of AP-1 phenotype in JB6 cells. In Vitro Cell. Dev. 

Biol. 32: 234-237, 1996. 

118. Sun Y, Kim H, Parker M, Stetler-Stevenson WG, and Colburn NH: Lack of suppression of 

tumor cell phenotype by overexpression of TIMP-3 in mouse JB6 tumor cells: Identification 

of a transfectant with increased tumorigenicity and invasiveness. Anticancer Res. 16: 1-8, 

1996. 

119. Dong Z, Xu R-H, Kim J, Zhan S-N, Ma, W-Y, Colburn NH, and Kung H-F: AP-1/Jun is 

required for early Xenopus development and mediates the mesoderm induction by FGF but 

not by activin. J. Biol. Chem. 271: 9942-9946, 1996. 

120. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, Kung H-F, Colburn NH and Sun 

Y: Suppression of in vivo tumor growth and induction of suspension cell death by tissue 

inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17: 1805-1811, 1996. 

121. Kim H, Pennie WD, Sun Y, and Colburn NH: Differential functional significance of AP-1 

binding sites in the promoter of gene encoding mouse tissue inhibitor of metalloproteinases- 

3. Biochem. J. 324: 547-553, 1997. 

122. Strickland J, Sun Y, Dong Z, and Colburn NH: Grafting assay distinguishes promotion 

sensitive from promotion resistant JB6 cells. Carcinogenesis 18: 1135-1138, 1997. 

123. Pennie WD, Sun Y, Kim H, and Colburn NH: Differential expression of TIMP-3 during 

neoplastic progression in the mouse JB6 model system. In Liang P, and Pardee AB (Eds): 

Differential Display, Methods, and Protocols. Totowa, NJ, Humana Press, 85: 249-261, 

1997. 

124. Dong Z, Ding M, Ma W-Y, and Colburn NH: Inhibition of tumor promoter induced 

transformation by expression of the small GTP-binding protein rac in JB6 cells. Int. J. 

Oncology 11: 157-161, 1997. 

125. Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, and Colburn NH: A 

dominant negative mutant of Jun blocking 12-0-Tetradecanoylphorbol-13-acetate-Induced 

invasion in mouse keratinocytes. Mol. Carcinog. 19: 204-212, 1997.

20 


126. Cmarik JL, and Colburn NH: Use of mouse JB6 cells to identify molecular targets and novel 

agents for prevention of carcinogenesis. Proc. International Conf. on Food Factors: 

Chemistry and Cancer Prevention. Ohigashi H et al., (eds.), Springer-Verlag, Tokyo, 67-76, 

1997. 

127. Saffer JD, Chen G, Colburn NH, and Thurston SJ: Power frequency magnetic fields do not 

contribute to transformation of JB6 cells. Carcinogenesis 18: 1365-1370, 1997. 

128. Li JJ, Westergaard C, Ghosh P, and Colburn NH: Inhibitors of both NF-κB and AP-1 

activation block neoplastic transformation response. Cancer Res. 57: 3569-3576, 1997. 

129. Smith MR, Kung H-F, Durum SK, Colburn NH, and Sun Y: TIMP-3 induces cell death by 

stabilizing TNF� receptors on the surface of human colon carcinoma cells. Cytokine 9: 770- 

780, 1997. 

130. Huang C, Ma W-Y, Young MR, Colburn NH, and Dong Z: Shortage of mitogen-activated 

protein (MAP) kinase is responsible for resistance to AP-1 transactivation and transformation 

in mouse JB6 P- cells. Proc. Natl. Acad. Sci. USA 95: 156-161, 1998. 

131. Li JJ, Rhim JS, Schlegel R, Vousden KH, and Colburn NH: Expression of dominant negative 

Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent 

growth of HPV immortalized human keratinocytes. Oncogene 16: 2711-2721, 1998. 

132. Li JJ, Colburn NH, and Oberley LW: Maspin gene expression in tumor suppression induced 

by overexpressing manganese-containing superoxide dismutase cDNA in human breast 

cancer cells. Carcinogenesis 5: 833-839, 1998. 

133. Cmarik JL, Li Y, Ogram SA, Reeves R, and Colburn NH: Tumor promoter induces high 

mobility group HMG-Y protein expression in transformation-sensitive but not resistant cells. 

Oncogene 16: 3387-3396, 1998. 

134. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, and Colburn NH: Expression 

of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. 

Oncogene 17: 3493-3498, 1998. 

135. Li J-J, Oberley LW, Fan M, and Colburn NH: Inhibition of AP-1 and NF-κB by manganesecontaining 

superoxide dismutase in human breast cancer cells. FASEB J.12: 1713-1723, 

1998. 

136. Gopalakrishna R, Gundimeda U, Anderson WB, Colburn NH, and Slaga TJ: Tumor promoter 

benzoyl peroxide induces sulfhydryl oxidation in protein kinase C: its reversibility is related

21 


to the cellular resistance to peroxide-induced cytotoxity. Arch. of Biochem. And Biophysics 

363: 246-258, 1999. 

137. Pennie WD, Hegamyer GA, Young MR, and Colburn NH: Specific methylation events 

contribute to the transcriptional repression of the mouse tissue inhibitor of 

metalloproteinases-3 gene (TIMP-3) in neoplastic cells. Cell Growth & Diff. 10:279-286, 

1999. 

138. Ding M, Li J-J, Leonard SS, Ye J-P, Shi X, Colburn NH, Castranova V, and Vallyathan V: 

Vanadate-induced activation of activator protein-1: Role of reactive oxygen species. 

Carcinogenesis 20:663-668, 1999. 

139. Young MR, Li J-J, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R, and Colburn 

NH: Transgenic mice demonstrate AP-1 transactivation is required for tumor promotion. 

Proc. Natl. Acad. Sci. USA 96: 9827-9832, 1999. 

140. Cmarik JL, Min H, Hegamyer GA, Zhan S, Matsuhashi S, Yoshinaga H, and Colburn NH: 

Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic 

transformation. Proc. Natl. Acad. Sci. USA 96: 14037-14042, 1999. 

141. Jansen AP, Colburn NH, and Verma AK: Tumor promoter-induced ornithine decarboxylase 

gene expression occurs independently of AP-1 activation. Oncogene 18:5806-13, 1999. 

142. Davis MA, Flaws JA, Young M, and Colburn NH: Effect of ceramide on intracellular 

glutathione determines apoptotic or necrotic cell death of JB6 tumor cells. Tox. Sci. 53: 48- 

55, 2000. 

143. Sun Y, Kim H, Bian J, Wang Y, Pennie W, and Colburn NH: Regulation of expression of the 

mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene. In Edward D, Khokha R, and 

Howkes S (Eds): Inhibitors of Metalloproteinases in Development and Disease: TIMPs, pp. 

25-23, 2000. 

144. Nakamura K, Sun Y, Yokoyama Y, Ferris D, Singh N, Ichikawa T, Shinozuka K, Kunitomo 

M, and Colburn NH: Phosphorylation status and function of P53 are inversely related to 

protein Kinase C activation. Anticancer Research 20:1-6, 2000. 

145. Cmarik JL, Hegamyer GA, Gerrard B, Dean M, and Colburn NH: cDNA cloning and 

mapping of mouse pleckstrin (Plek), a gene upregulated in transformation-resistant cells. 

Genomics 66:204-212, 2000. 

146. Hsu T-C, Young MR, Cmarik J, and Colburn NH: Activator protein-1- (AP-1) and nuclear 

factor-�B (-�B)-dependent transcriptional events in carcinogenesis. FORUM Free Radical

Biology & Medicine 28: 1338-1348, 2000. 

22 


147. Li J-J, Cao Y, Young MR, and Colburn NH: Induced expression of dominant negative cJun 

down regulates NF-�B and AP-1 target genes and suppresses tumor phenotype in human 

keratinocytes. Molec. Carcinogenesis 29:159-169, 2000. 

148. Yang H-S, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, and Colburn NH: A 

novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-�B or 

ODC transactivation. Oncogene 20: 669-676, 2001. 

149. Hsu T-C, Nair R, Tulsian P, Camalier C, Hegamyer GA, Young MR, and Colburn NH: 

Transformation non-responsive cells owe their resistance to lack of P65/NF-�B activation. 


150. Young MR, Nair R, Bucheimer N, Tulsian P, Hsu T-C, and Colburn NH: Transactivation of 

Fra-1 and consequent activation of AP-1 occur Erk dependently. Mol. Cell Biol. 22: 587- 

598, 2002. 

151. Shimamura T, Hsu T-C, Colburn NH, and Bejcek BE: Activation of NF-�B is required for 

PDGF-B chain to transform NIH3T3 cells. Exp. Cell Research 274: 157-167, 2002. 

152. Suzukawa K and Colburn NH: AP-1 transrepressing retinoic acid does not deplete 

coactivators or AP-1 monomers but may target Jun-Fos dimers. Oncogene 21: 2181-2190, 

2002. 

153. Young MR, Farrell L, Lambert P, Awasthi P, and Colburn NH: Protection against human 

papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of 

dominant-negative c-jun. Molecular Carcin. 34: 72-77, 2002. 

154. Thompson EJ, MacGowan J, Young MR, Colburn NH, and Bowden GT: A dominant 

negative c-jun specifically blocks okadaic acid induced skin tumor promotion. Cancer Res. 

62: 3044-3047, 2002. 

155. Yu CY, Wang L, Khaletskiy A, Farrar WL, Larner A, Colburn NH, and Li JJ: STAT3 

activation is required for interleukin-6 induced transformation in tumor-promotion sensitive 

mouse skin epithelial cells. Oncogene 21: 3949-3960, 2002. 

156. Dhar A, Young MR, and Colburn NH: The role of AP-1, NF-�B and ROS/NOS in skin 

carcinogenesis: The JB6 model is predictive. Mole. Cell Biochem. 234: 185-193, 2002. 

157.

23 


158. Suzukawa K, Weber TJ, and Colburn NH: AP-1, NF-�B and Erk activation thresholds for 

neoplastic transformation in the mouse epidermal JB6 model. Env. Health Perspectives 110 

(9): 865-870, 2002. 

159. Willis DB and Colburn NH: Molecular targets for cancer prevention: a meeting review. 

Cancer Epid. & Biomarkers 11: 972-8, 2002. 

160. Yang, HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes X, Lockett SJ, Sonenberg 

N, and Colburn NH: The transformation suppressor Pdcd4 is a novel eukaryotic 

transformation initiation factor 4A binding protein that inhibits translation. Mole. Cell Biol. 

23: 26-37, 2003. 

161. Young MR, Yang HS, and Colburn NH: Promising molecular targets for cancer prevention: 

AP-1, NF-�B, and Pdcd4. Trends in Mole. Med. 9: 36-41, 2003. 

162. Yang HS, Knies JL, Stark C, and Colburn NH: Pdcd4 suppresses tumor phenotype in JB6 

cells by inhibiting AP-1 transactivation. Oncogene 22: 3712-3720, 2003. 

163. Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, and Colburn NH: Nitric oxide does not 

mediate but inhibits transformation and tumor phenotype. Mole. Cancer Thera. 2: 1285- 

1293, 2003. 

164. Cooper S, Young MR, Colburn NH, and Bowden GT: Expression of Dominant Negative cjun 

Inhibits UVB Induced Squamous Cell Carcinoma Number and Size in an SKH-1 Hairless 

Mouse Model. Mole. Cancer Res. 1: 848-854, 2003. 

165. Hou D-X, Kai K, Li J-J, Lin S, Terahara N, Wakamatsu M, Fujii M, Young MR, and 

Colburn NH: Anthocyanidins inhibit activator protein l activity and cell transformation: 

structure-activity relationship and molecular mechanisms. Carcinogenesis 25: 29-36, 2004. 

166. Jansen AP, Camalier C, Stark C, and Colburn NH: Characterization of programmed cell 

death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mole. 

Cancer Therap. 3: 103-110, 2004. 

167. Yang HS, Cho M-H, Zakowicz H, Hegamyer GA, Sonenberg N, and Colburn NH: A novel 

function of the MA-3 domains in the transformation and translation suppressor Pdcd4 is 

essential for its binding to eIF4A. Mole. Cell. Biol. 24: 3894-3906, 2004. 

168. Dhar A, Hu J, Reeves R, and Colburn NH: Dominant-negative c-Jun (TAM67) target genes: 

HMGA1 is required for tumor promoter-induced transformation. Oncogene 23: 4466-4476, 

2004.

24 


169. Hu J, Nakano H, Sakurai H, and Colburn NH: Insufficient p65 phosphorylation at S536 

specifically contributes to the lack of NF-κB activation and transformation in resistant JB6 

cells. Carcinogenesis 25: 1991-2003, 2004. 

170. Kim HW, Park IK, Cho CS, Lee KH, Beck Jr. GR, Colburn NH, and Cho MH: Aerosol 

delivery of glucosylated polyethylenimine (GPEI)/PTEN complex suppressed Akt 

downstream pathways in the lung of K-ras knock-out mice. Cancer Research 64: 7971- 

7976, 2004. 

171. Zakowicz H, Yang H-S, Stark C, Wlodawer A, LaRonde-LeBlanc N, and Colburn NH: 

Mutational analysis of the DEAD box RNA helicase eIF4AII characterizes its interaction 

with Pdcd4 and eIF4GI. RNA 11:261-274, 2005. 

172. Hu J and Colburn NH: Histone deacetylase inhibition down-regulates cyclin D1 

transcription by inhibiting NF-�B/p65 DNA binding. Mol. Can. Res. 3: 100-109, 2005. 

173. Zhao Y, Chaiswing L, Velez JJ, Batinic-Haberle I, Colburn NH, Oberley TD, and St. Clair 

DK: p53 translocation to mitochondria precedes its nuclear translocation and targets 

mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 65: 

3745-3750, 2005. 

174. Weber TJ, Markillie LM, Chrisler WB, Lei XC, and Colburn NH: Dual regulation of JB6 

transformation by low dose gamma radiation. Mole. Carcinogenesis 43: 321-37, 2005. 

175. Jansen AP, Camalier CE, and Colburn NH: Epidermal expression of the translation inhibitor 

programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65: 6034-6041, 2005. 

176. Hu J, Haseebuddin M, Young MR, and Colburn NH: Suppression of p65 phosphorylation 

coincides with inhibition of I�B� polyubiquitination and degradation. Molec. Carc. 44: 

274-284, 2005. 

177. Guo D, Han J, Adam BL, Colburn NH, Wang MH, Dong Z, Eizirik DL, She JX, and Wang 

CY: Proteomic analysis of SUMP4 substrates in HEK293 cells under serum starvationinduced 

stress. Biochem. Biophys. Res. Commun. 337: 1308-1318, 2005. 

178. Yang H-S, Matthews CP, Clair T, Wang Q, Baker AR, Li C-C, Tan T-H, and Colburn NH: 

Tumorigenesis suppressor Pdcd4 down-regulates MAP4K1 expression to suppress colon 

carcinoma cell invasion. Molec. Cell. Biol. 26: 1297-1306, 2006. 

179. Jin J, Kim TH, Hwang S-K, Chang S-H, Kim HW, Anderson JK, Lee H-W, Lee K-H, 

Colburn NH, Yang H-S, Cho M-H, and Cho CS: Aerosol delivery of urocanic acid-modified

25 


chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis 

in lungs of K-ras null mice. Mol. Cancer Ther. 5: 1041-1049, 2006. 

180. Shen Q, Zhang Y, Uray I, Hill J, Kim H-T, Lu C, Young MR, Gunther E, Hilsenbeck S, 

Chodosh L, Colburn NH, and Brown PR: The AP-1 transcription factor regulates postnatal 

mammary gland development. Dev. Bio. 295: 589-603, 2006. 

181. Young MR and Colburn NH: Fra-1 a target for cancer prevention or intervention. Gene 379: 

1-11, 2006. 

182. Chang SH, Yu KN, Lee YS, An GH, Beck Jr. GR, Colburn NH, Lee KH, and Cho MH.: 

Elevated inorganic phosphate stimulates AKT-ERK1/2-Mnk1 signaling in human lung cells. 

Am. J. Respir. Cell. Mol. Biol. 35: 528-539, 2006. 

183. Dorrello NV Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, and Pagano M: 

S6K1- and βTRCP-mediated degradation of Pdcd4 promotes protein translation and cell 

growth. Science 314: 467-471, 2006. 

184. Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, and Henrich CJ: A 

High-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1. 

J. Biomol. Screen 12: 133-139, 2007. 

185. LaRonde-LeBlanc N, Santhanam AN, Baker AR, Wlodawer A, and Colburn, NH: Structural 

basis for inhibition of translation by the tumor suppressor Pdcd4. Mol. Cell. Biol. 27: 147- 

156, 2007. 

186. Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck Jr. GR, Young MR, and Colburn 

NH: Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and 

osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res. 

67(6): 2430-2438, 2007. 

187. Matthews CP, Colburn NH, and Young MR: AP-1 a target for cancer prevention. Curr. 

Cancer Drug Targets 7(4): 317-324, 2007. 

188. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, and Allgayer H: Tumor suppressor 

Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene 

expression via Sp-transcription factors. Oncogene 26(31): 4550-4562, 2007. 

189. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko 

M, Kornblau S, and Lopez Berestein G: Programmed cell death-4 tumor suppressor protein 

contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid 

leukemia cells. Mole. Cancer Res. 5: 95-108, 2007.

26 


190. Hwang SK, Jin H, Kwon JT, Chang SH, Kim TH, Cho CS, Lee KH, Young MR, Colburn 

NH, Beck GR Jr, Yang HS, and Cho MH: Aerosol-delivered programmed cell death 4 

enhanced apoptosis, controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 

luciferase reporter mice. Gene Ther. 14(18): 1353-1361, 2007. 

191. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, 

Colburn NH, and Allgayer H: Loss of programmed cell death 4 expression marks adenomacarcinoma 

transition, correlates inversely with phosphorylated protein kinase B and is an 

independent prognostic factor in resected colorectal cancer. Cancer 110(8): 1697-1707, 

2007. 

192. Matthews CP, Colburn NH, and Young MR: AP-1 a target for cancer prevention. Curr. 

Cancer Drug Targets 7(4): 317-324, 2007. 

193. Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck Jr. GR, Young MR, and Colburn 

NH: Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and 

osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res. 

67(6): 2430-2438, 2007. 

194. Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, and Henrich CJ: A 

High-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1. 

J. Biomol. Screen 12: 133-139, 2007. 

195. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S and Allgayer H: 

MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and 

stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15): 

2128-2136, 2008. 

196. Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, and Colburn NH: Translation 

inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 68(5): 

1254-1260, 2008. 

197. Colburn N and Kensler T: Targeting transcription factors for cancer prevention – the case of 

Nrf2. Cancer Prev. Res. 1: 153-155, 2008. 

198. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu X-C, Young MR, Gunther EJ, Hilsenbeck SG, 

Colburn NH, Chodosh LA, and Brown PH: Targeting the AP-1 transcription factor for the 

prevention of estrogen receptor (ER)-negative mammary tumors. Cancer Prev. Res. 1(1):45- 

55, 2008.

27 


199. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, and Li Y: MicroRNA-21 

promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 

27(31): 4373-4379, 2008. 

200. Bobe G, Barrett KG, Mentor-Marcel RA, Saffiotti U, Young MR, Colburn NH, Albert PS, 

Bennink MR, and Lanza E: Dietary cooked navy beans and their fractions attenuate colon 

carcinogenesis in azoxymethane-induced ob/ob obese mice. Nutr. Cancer 60(3):373-381, 

2008. 

201. Song C, Xiao Z, Nagashima K, Li CC, Lockett SJ, Dai RM, Cho EH, Conrads TP, Veenstra 

TD, Colburn NH, Wang Q, and Wang JM: The heavy metal cadmium induces valosincontaining 

protein (VCP)-mediated aggresome formation. Toxicol. Appl. Pharmacol. 228(3): 

351-63, 2008. 

202. Abate-Shen A, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson W, and 

Threadgill D: The untapped potential of genetically-engineered mouse models in 

chemoprevention research: Opportunities and challenges. Cancer Prev. Res. 1(3): 161-166, 

2008. 

203. Duan D, Sigano DM, Kelley JA, Lai CC, Lewin NE, Kedei N, Peach MG, Lee J, Abeyweera 

TP, Rotenberg SA, Kim H, Kim YH, El Kazzouli S, Chung J-U, Young HA, Young MR, 

Baker A, Colburn NH, Haimovitz-Friedman A, Truman J-P, Parrish DA, Deschamps JR, 

Perry NA, Surawski RJ, Blumberg PM and Marquez VE: Conformationally constrained 

analogues of diacylglycerol cells sort diacylglycerol-lactone chemical zip codes to produce 

diverse and selective biological activities. J. Med. Chem. 51(17): 5198-5220, 2008. 

204. Wei Q, Jiang H, Matthews CP, and Colburn NH: Sulfiredoxin is an AP-1 target gene that is 

required for transformation and shows elevated expression in human skin malignancies. 

Proc. Natl. Acad. Sci. USA 105(50): 19738-19743, 2008. 

205. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu X-C, Young MR, Gunther EJ, Hilsenbeck SG, 

Colburn NH, Chodosh LA, and Brown PH: Targeting the AP-1 transcription factor for the 

prevention of estrogen receptor (ER)-negative mammary tumors. Cancer Prev. Res. 1(1):45- 

55, 2008. 

206. Nieves-Alicea R, Colburn NH, Simeone A-M, and Tari AM: Programmed cell death 4 

inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 

expression. Breast Cancer Res. Treat. 114(2): 203-209, 2009.

28 


207. Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, and Perantoni AO: Nitric oxide 

prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild type p53. Oncogene 

28(4): 619-624, 2009. 

208. Mentor-Marcel R, Bobe G, Barrett K, Young M, Albert P, Bennink M, Lanza, E, Colburn N: 

Inflammation-associated serum and colon markers as indicators of dietary attenuation of 

colon carcinogenesis in ob/ob mice. Cancer Prev. Res, 2(1): 60-69, 2009. 

209. Young MR, Ileva LV, Bernardo M, Riffle LA, Jones YL, Kim YS, Colburn NH, and Choyke 

PL: Monitoring of tumor promotion and progression in a mouse model of inflammation- 

induced colon cancer with Magnetic Resonance Colonography. Neoplasia 11(3): 237-246, 

2009. 

210. Kim Y, Young M, Bobe G, Colburn N and Milner J: Bioactive food components, 

inflammatory targets, and cancer prevention. Cancer Prev. Res. 2(3): 200-208, 2009. 

211. Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, 

Colburn NH: A selective small-molecule nuclear factor-κB inhibitor from a high-throughput 

cell-based assay for "activator protein-1 hits." Mole. Cancer Ther. 8(3): 571-581, 2009. 

212. Zhao C, Ivanov I, Dougherty ER, Hartman TJ, Lanza E, Bobe G, Colburn NH, Lupton JR, 

Davidson LA, and Chapkin RS: Non-invasive detection of candidate molecular biomarkers 

in subjects with a history of insulin resistance and colorectal adenomas. Cancer Prev. Res. 

2(6): 590-597, 2009. 

213. Yasuda M, Nishizawa T, Ohigashi H, Tanaka T, Hou DX, Colburn NH, and Murakami A: 

Linoleic acid metabolite suppresses skin inflammation and tumor promotion in mice: 

Possible roles of programmed cell death 4 induction. Carcinogenesis 30(7): 1209-1216, 

2009. 

214. Santhanam A, Bindewald E, Vinagolu RK, Larsson O, Sonenberg, N, Colburn NH, and 

Shapiro BA: Role of 3’UTRs in the translation of mRNAs regulated by oncogenic eIF4E- a 

computational inference. PLoS One 4(3): e4868, 2009. 

215. Yin Y, Wang S, Sun Y, Young M, Colburn NH, Shu Y, and Han X: JNK/AP-1 pathway is 

involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth 

factor in MCF7 cells. Biomed Pharmacother. 63(6): 429-435, 2009. 

216. Beutler JA, Kang MI, Robert F, Clement JA, Pelletier J, Colburn NH, McKee TC, 

Goncharova E, McMahon JB, and Henrich CJ: Quassinoid inhibition of AP-1 function does

29 


not correlate with cytotoxicity or protein synthesis inhibition (dagger). J. Nat. Prod. 72(3): 

503-506, 2009. 

217. Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, 

Colburn NH: A selective small-molecule nuclear factor-κB inhibitor from a high-throughput 

cell-based assay for "activator protein-1 hits." Mole. Cancer Ther. 8(3): 571-581, 2009. 

218. Tichelaar JW, Yan Y, Tan Q, Wang Y, Estensen RD, Young MR, Colburn NH, Yin H, 

Goodin C, Anderson MW, and You M: A Dominant-Negative c-jun Mutant Inhibits Lung 

Carcinogenesis in Mice. Cancer Prev. Res. 3(9): 1148-1156, 2010. 

219. Hartman TJ, Albert PS, Zhang Z, Bagshaw D, Kris-Etherton PM, Ulbrecht J, Miller CK, 

Bobe G, Colburn NH, and Lanza E: Consumption of a legume-enriched, low-glycemic Index 

diet is associated with biomarkers of insulin resistance and inflammation among men at risk 

for colorectal cancer. J Nutr. 140(1): 60-67, 2010. 

220. Blees JS, Schmid T, Thomas CL, Baker AR, Benson L, Evans JR, Goncharova EI, Colburn 

NH, McMahon JB, Henrich CJ: Development of a high-throughput cell-based reporter assay 

to identify stabilizers of tumor suppressor Pdcd4. J. Biomol. Screen. 15(1): 21-29, 2010. 

221. Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH, and Beck GR Jr: Elevated 

phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer 

Prev. Res. 3(3):359-370, 2010. 

222. Young MR, Santhanam AN, Yoshikawa N, and Colburn NH: Have tumor suppressor 

PDCD4 and its counteragent oncogenic miR-21 gone rogue? Mol. Interv. 10(2):76-79, 2010. 

223. Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J, and Colburn 

NH: STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev. 

Res. (Phila Pa) 3(4): 495-504, 2010. 

224. Yasuda M, Schmid T, Rubsamen D, Colburn NH, Irie K and Murakami A: Downregulation 

of programmed cell death 4 by inflammatory conditions contributes to the generation of the 

tumor promoting microenvironment. Mol. Carcinog. 49(9): 837-848, 2010. 

225. Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ: 

Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by 

dietary flavonols in the polyp prevention trial. Cancer Prev. Res. 3(6): 764-775, 2010.

30 


226. Santhanam AN, Baker AR, Hegamyer G, Kirschmann DA, and Colburn NH: Pdcd4 

repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene 

29(27): 3921-3932, 2010. 

227. Tichelaar JW, Yan Y, Tan Q, Wang Y, Estensen RD, Young MR, Colburn NH, Yin H, 

Goodin C, Anderson MW, and You M: A Dominant-Negative c-jun Mutant Inhibits Lung 

Carcinogenesis in Mice. Cancer Prev. Res. 3(9): 1148-1156, 2010. 

228. Zhang Z, Lanza E, Kris-Etherton PM, Colburn NH, Bagshaw D, Rovine MJ, Ulbrecht JS, 

Bobe G, Chapkin RS, and Hartman TJ: A high legume low glycemic index diet improves 

serum lipid profiles in men. Lipids 45(9): 765-775, 2010. 

229. Bobe G, Murphy G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, and Cross 

AJ: Serum cytokine concentrations, flavonol intake and colorectal adenoma recurrence in 

the Polyp Prevention Trial. Br. J. Cancer 103(9): 1453-1461, 2010. 

230. Bobe G, Murphy G, Albert PS, Sansbury LB, Young MR, Lanza E, Schatzkin A, Colburn 

NH, and Cross AJ: Do interleukin polymorphisms play a role in the prevention of colorectal 

adenoma recurrence by dietary flavonols? Eur. J. Cancer Prev. 20(2): 86-95, 2011. 

231. Zhang Z, Lanza E, Ross AC, Albert PS, Colburn NH, Rovine MJ, Bagshaw D, Ulbrecht JS, 

and Hartman TJ: A high-legume low-glycemic index diet reduces fasting plasma leptin in 

middle-aged insulin-resistant and -sensitive men. Eur J. Clin. Nutr. 65(3): 415-418, 2011. 

232. Devkota KP, Ratnayake R, Colburn NH, Wilson JA, Henrich CJ, McMahon JB, and Beutler 

JA: Inhibitors of the oncogenic transcription factor AP-1 from Podocarpus latifolius. J. Nat. 

Prod. 74(3): 374-377, 2011. 

233. Wei Q, Jiang H, Xiao Z, Baker A, Young M, Veenstra T, and Colburn NH: The Srx-Prx IV 

Axis Promotes human lung cancer progression through modulation of specific 

phosphokinase signaling. Proc. Natl. Acad. Sci. USA 108(17): 7004-7009, 2011. 

234. Grkovic T, Blees JS, Colburn, NH, Schmid T, Thomas CL, Hendrich CJ, McMahon JB, and 

Gustafson KR: Cryptocaryols A-H, a-pyrone-containing, 1,3-polyols from cryptocarya sp. 

implicated in stabilizing the tumor suppressor Pcdc4. J. Nat. Prod. 74(5): 1015-1020, 2011. 

235. Gaur AB, Holbeck SL, Colburn NH, and Israel MA: Downregulation of Pdcd4 by mir-21 

facilitates glioblastoma proliferation in vivo. Neuro. Oncol. 13(6): 580-590, 2011. 

236. Diyabalanage T, Ratnayake R, Wilson JA, Henrick CJ, Beutler JA, Colburn NH, McMahon 

JB, and Gustafson, KR: Nothospondin, a new AP-1 inhibitory quassinoid from the

31 


Cameroonian plant Nothospondias staudtii. Bioorg. Med. Chem. Lett. 21(15): 4397-4399, 

2011. 

237. Noubissi FK, Nikivorov MA, Colburn NH, and Spiegelman VS: Transcriptional regulation 

of CRD-BP by c-myc: Implications for c-myc functions. Genes Cancer 1(10): 1074-1082, 

2011. 

238. Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, Rübsamen D, Schulz K, Weigert A, 

Baker AR, Colburn NH, and Brüne B: Inflammation-induced loss of Pdcd4 is mediated by 

phosphorylation-dependent degradation. Carcinogenesis 32(10):1427-1433, 2011. 

239. Popplewell WL, Ratnayake R, Wilson JA, Beutler JA, Colburn NH, Henrich CJ, McMahon 

JB, and McKee TC: Grassypeptolides F and G, cyanobacterial peptides from Lyngbya 

majuscula. J. Nat. Prod. 74(8): 1686-1691, 2011. 

240. Zhao LX, Huang SX, Tang SK, Jiang CL, Duan Y, Beutler JA, Henrich CJ, McMahon JB, 

Schmid T, Blees JS, Colburn NH, Rajski SR, and Shen B: Actinopolysporins A-C and 

tubercidin as Pdcd4 stabilizer from the halophilic actinomycete actinopolyspora erythraea 

YIM 90600. J. Nat. Prod. 74(9): 1990-1995, 2011. 

241. Young M, Hu Y, and Colburn NH: NF-κB. In: Encyclopedia of Cancer Therapeutic Targets, 

Springer Science & Business Media, LLC, New York, NY, in press, 2011. 

242. Dong S, Cahill KJ, Kang MI, Colburn NH, Henrich CJ, Wilson JA, Beutler JA, Johnson RP, 

and Porco JA: Microwave-based reaction screening: Tandem retro-diels-adler cycloadditions 

of ortho-quinol dimers. J. Org. Chem. 76(21): 8944-8954, 2011. 

243. Hartman T, Zhang Z, Albert P, Bagshaw D, Mentor-Marcel R, Mitchell D, Colburn N, 

Kris-Etherton P, Lanza E: Reduced Intake and weight loss on a legume-enriched diet lead to 

improvements in biomarkers related to chronic disease. Topics in Clinical Nutrition. 

(26)3: 208-215, 2012.

Dr. Colburn Curriculum Vitae 2012 - Center for Cancer Research ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?